Login to Your Account

Nightstarx gene therapy may help restore vision to choroideremia patients

By Nuala Moran
Staff Writer

Thursday, January 30, 2014

LONDON – Nightstarx Ltd. has been launched with £12 million (US$19.8 million) funding to commercialize a gene therapy that has been demonstrated to partly restore vision in patients losing their eyesight as a result of the X-linked inherited disorder, choroideremia.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription